Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear transport factor 2 (NUTF2) is a small cytosolic protein essential for nuclear import of GDP-bound Ran, a small Ras-like GTPase, thus playing a central role in nucleocytoplasmic transport. NUTF2 interacts with components of the nuclear pore complex, particularly nucleoporin 62, to facilitate the trafficking of proteins into the nucleus following initial docking steps. NUTF2 expression is upregulated in several types of cancers, including head and neck squamous cell carcinoma, glioma, and melanoma, and its elevated levels correlate with larger tumor size and poorer patient survival. The protein also influences immune responsivity within the tumor microenvironment, serving both as a potential therapeutic target and prognostic biomarker. Despite these associations, no approved drugs currently target NUTF2 directly, and information on therapeutic mechanisms or drug safety specific to NUTF2 is lacking[1][2][3][4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear transport factor 2 (NUTF2).